68Ga-grazytracer PET/CT of Tumor Responses to Immunotherapy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 22, 2021

Primary Completion Date

May 25, 2024

Study Completion Date

May 31, 2024

Conditions
Cancer
Interventions
DRUG

68Ga-grazytracer

68Ga-grazytracer PET/CT: after intravenous injection of 2.96-3.7 MBq/kg body weight of quality-controlled 68Ga-grazytracer, a Biograph mCT Flow 64 scanner or Total-body PET/CT uEXPLORER scanner will be applied, and the scan range will be from the top of the head to 1/3 of the upper thigh.

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

All Listed Sponsors
collaborator

Peking University Health Science Center

OTHER

lead

Peking University Cancer Hospital & Institute

OTHER

NCT05000372 - 68Ga-grazytracer PET/CT of Tumor Responses to Immunotherapy | Biotech Hunter | Biotech Hunter